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The polygenic risk for obsessive-compulsive
disorder is associated with the personality
trait harm avoidance
Bey K, Weinhold L, Gr€utzmann R, Heinzel S, Kaufmann C, Klawohn
J, Riesel A, Lennertz L, Schmid M, Ramirez A, Kathmann N, Wagner
M. The polygenic risk for obsessive-compulsive disorder is associated
with the personality trait harm avoidance.
Objective: Obsessive-compulsive disorder (OCD) is a complex
psychiatric disorder with a substantial genetic contribution. While the
specific variants underlying OCD’s heritability are still unknown,
findings from genome-wide association studies (GWAS) corroborate
the importance of common SNPs explaining the phenotypic variance in
OCD. Investigating associations between the genetic liability for OCD,
as reflected by a polygenic risk score (PRS), and potential
endophenotypes of the disorder, such as the personality trait harm
avoidance, may aid the understanding of functional pathways from
genes to diagnostic phenotypes.
Methods: We derived PRS for OCD at several P-value thresholds based
on the latest Psychiatric Genomics Consortium OCD GWAS (2688
cases, 7037 controls) in an independent sample of OCD patients
(n = 180), their unaffected first-degree relatives (n = 108) and healthy
controls (n = 200). Using linear regression, we tested whether these
PRS are associated with the personality trait harm avoidance.
Results: Results showed that OCD PRS significantly predicted OCD
status, with patients having the highest scores and relatives having
intermediate scores. Furthermore, the genetic risk for OCD was
associated with harm avoidance across the entire sample, and among
OCD patients. As indicated by mediation analyses, harm avoidance
mediated the association between the OCD PRS and OCD caseness.
These results were observed at multiple P-value thresholds and persisted
after the exclusion of patients with a current comorbid major depressive
or anxiety disorder.
Conclusion: Our findings support the polygenic nature of OCD and
further validate harm avoidance as a candidate endophenotype and
diathesis of OCD.
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Significant outcomes
• Polygenic risk scores for OCD are associated with the personality trait harm avoidance.
• The findings support the polygenic nature of OCD and further validate harm avoidance as a candi-
date endophenotype and diathesis of OCD.
Limitation
• The sample sizes of the discovery and target samples are relatively small.
• The association between the polygenic risk score for OCD and harm avoidance did not remain signif-
icant when unaffected first-degree relatives and controls were analyzed separately.
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Obsessive-compulsive disorder (OCD) is a debili-
tating and often chronic psychiatric disorder char-
acterized by obsessions (intrusive unwanted
thoughts or images) and/or compulsions (ritualized
repetitive behaviors), which affects 1–3% of the
population worldwide (1). OCD is familial, with
first-degree relatives having an approximately five-
fold increased risk of also being affected by the dis-
ease (2–4). Twin studies of OCD and OCD-related
traits estimated a heritability of around 27–47% in
adults, and 45–65% in children (5–7). Though
recent evidence supports the involvement of rare
and de novo variants (8–10), a major proportion
of OCD’s heritability appears to stem from com-
mon genetic variants (minor allele frequency
(MAF) > 5%), with an estimated single nucleotide
polymorphism (SNP)-based heritability of 28–42%
(11, 12). In fact, around 65% of OCD’s SNP-based
heritability is accounted for by SNPs with a
MAF ≥ 40% (12). Thus, the majority of the
genetic variability underlying the heritability esti-
mates from family studies in OCD seems to be cap-
tured by GWAS. Yet, the specific variants
underlying the disorder are largely unknown, as no
genome-wide significant associations have been
found so far in case–control GWAS, possibly
because of the limited sample size of these analyses
(combined 2688 cases, 7037 controls) (12–14).
Investigating endophenotypes, which are heritable,
quantitative traits associated with the disease and
observed in unaffected relatives of patients, may
aid the understanding of functional pathways from
genes to diagnostic phenotypes (15). Since
endophenotypes are supposed to share underlying
genetic factors with the clinical disorder, they
should be associated with specific genetic risk vari-
ants for the disease (16) and thus represent geneti-
cally driven vulnerability factors.
One of the best-validated candidate endopheno-
types of OCD is the personality trait harm avoid-
ance. Conceptualized as a temperament dimension
in Cloninger’s biosocial model of personality,
harm avoidance is defined as an automatic ten-
dency to respond intensely to aversive stimuli (17).
People scoring high on this trait are characterized
by excessive worrying, fear of uncertainty, shyness
and fatigability. With heritability estimates ranging
from 42% to 57%, harm avoidance has a strong
genetic contribution (18–20) and is highly stable
throughout life (21). In line with Cloninger’s and
Svrakic’s proposal that individual configurations
in personality structure influence the risk of psy-
chopathology (17), high levels of harm avoidance
have repeatedly been associated with various
psychiatric disorders, including OCD (22–24).
Within the framework of the Core Dimensions
Model of OCD, harm avoidance is considered one
of two central motivators underlying the disorder
(25). Most notably, increased levels of harm avoid-
ance have also been observed in unaffected first-de-
gree relatives of OCD patients (26–28). This suggests
that harm avoidance may partially mediate the
genetic risk for OCD, but this hypothesis has not
been tested using molecular genetic methods, so far.
To assess the association between the genetic
underpinnings of OCD and a potential endophe-
notype, polygenic risk scores (PRS) can be
employed, which represent the combined effect of
a large number of SNPs (29). Based on the sum-
mary statistics of an independent GWAS, various
PRS can be calculated by including SNPs with a P-
value smaller than a predefined threshold of signifi-
cance. As almost all of OCD’s heritability is
explained by variance in common SNPs, PRS
based on common variants are a valid approach to
capture the genetic liability for this disease.
Several studies have investigated the relationship
between endophenotypes and PRS for psychiatric
disorders other than OCD, supporting the assump-
tion that common genetic variants associated with
a specific disorder also predict cognitive perfor-
mance, psychological trait measures as well as
brain structure and function (30–34). In a large
population-based sample, Taylor et al. found that
genetic factors associated with psychiatric disor-
ders, including OCD, are related to subclinical
traits throughout the general population (35). Fur-
thermore, a PRS for OCD predicted obsessive-
compulsive symptoms in a population-based twin-
family sample (36). However, the specific associa-
tion between relevant endophenotypes of OCD
and OCD-derived PRS has not been examined sys-
tematically.
Aims of the study
In the present study, we aimed to investigate
whether the genetic risk for OCD, as defined by a
PRS derived from GWAS data on OCD, is associ-
ated with the personality trait harm avoidance in a
sample of OCD patients, their unaffected first-de-
gree relatives and healthy control subjects. The
examination of relatives of OCD patients has the
advantage that these subjects have a higher genetic
load than controls but are not afflicted by the con-
founds of the disease itself (32). Our sample thus
allowed for the validation of harm avoidance as an
endophenotype at both the phenotypic and the
genetic level. To account for the phenotypic
heterogeneity of OCD, age of onset and symptom
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dimensions were considered as potential modula-
tion factors.
Methods and Materials
Sample and clinical assessment
The sample consisted of 180 patients with OCD,
200 healthy comparison subjects and 108 unaf-
fected first-degree relatives of OCD patients, who
participated in the EPOC (Endophenotypes of
OCD) study (26, 37). Sample characteristics are
presented in Table 1. OCD patients and relatives
were recruited via the outpatient clinics at the
Department of Psychology of Humboldt-Univer-
sit€at zu Berlin and at the Department of Psychiatry
and Psychotherapy of the University Hospital
Bonn, Germany. Healthy volunteers were recruited
from the general population via public advertise-
ments. All participants were examined by trained
clinical psychologists using the Structured Clinical
Interview for DSM-IV (SCID-I) (38, 39). To estab-
lish cross-site reliability of clinical ratings, all
instructions were standardized and raters com-
pleted assessments of four training videos. Patients
and relatives were only included if they were (i)
free of past or present psychotic, bipolar or sub-
stance-related disorders; (ii) did not take neurolep-
tic medication for the previous four weeks; and
(iii) did not use benzodiazepines in the prior two
weeks. Additionally, healthy controls were
excluded if they (i) took any psychoactive medica-
tion in the previous three months; (ii) had a current
Axis I disorder; (iii) had a lifetime diagnosis of
OCD or tic disorder; or (iv) had a family history of
OCD. All relatives were free of past or present
OCD.
Consistent with the concept of endopheno-
types being state-independent, OCD patients
varied with respect to cognitive behavioral and
medical treatment (see Table S1). Ninety OCD
patients were medicated with selective serotonin
reuptake inhibitors (SSRIs) and/or other antide-
pressants in the previous four weeks. Further-
more, the majority of patients had one or more
comorbid Axis I disorders, with major depres-
sion being the most common comorbidity
(n = 41 current episode, n = 69 remitted). A
total of n = 34 had a current comorbid anxiety
disorder, that is, panic disorder with/without
agoraphobia, agoraphobia, social phobia, speci-
fic phobia, or generalized anxiety disorder, as
assessed by the SCID-I interview.
Written informed consent was obtained and par-
ticipants were compensated for their time. The
study was in accordance with the revised Declara-
tion of Helsinki and approved by the local ethics
committees of the Charite Universit€atsmedizin
Berlin and the University Hospital Bonn.
Measures
Harm avoidance was assessed using the German
version of the Temperament and Character Inven-
tory (TCI) (40, 41). For each subject, a sum score
was computed based on the 35 binary items of the
harm avoidance scale. Cronbach’s a of the global
scale was a = 0.92, indicating high internal consis-
tency. The severity of OCD symptoms was evalu-
ated with the German versions of the Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) (42, 43)
and the Obsessive-Compulsive Inventory-Revised
(OCI-R), which comprises five subscales, that is,
washing, obsessing, ordering, neutralizing and
hoarding (44, 45). Here, we specifically focused on
the obsessing and ordering subscales, since the for-
mer has been strongly and uniquely linked to harm
avoidance, while the latter is proposed to be unre-
lated to harm avoidance (46, 47). Internal consis-
tencies were a = 0.86 for the Y-BOCS total score,






N 180 108 200
Mean age, years (SD) 33.18 (10.66) 47.19 (13.91) 34.77 (12.67) F(2, 485) = 49.27 <0.001
Gender, % male 41.7 33.3 36.5 Χ2(2) = 3.33 0.19
Education (SD)† 4.97 (1.85) 4.76 (2.01) 5.22 (1.58) Χ2(2) = 3.30 0.19
Mean harm avoidance score (SD) 22.18 (6.99) 14.85 (6.31) 10.74 (5.32) F(2, 485) = 163.34 < 0.001
Mean OCI-R score (SD) 27.26 (11.72) 6.83 (6.64) 4.63 (4.54) F(2, 485) = 398.46 < 0.001
Mean obsessing subscale (SD) 6.92 (3.33) 1.10 (1.52) 0.64 (1.15) F(2, 485) = 414.75 < 0.001
Mean ordering subscale (SD) 4.58 (3.43) 1.92 (2.23) 1.32 (1.57) F(2, 485) = 83.69 < 0.001
Mean Y-BOCS score (SD)‡ 22.22 (6.71)
Mean age of onset (SD)‡ 21.23 (10.73)
OCD, obsessive-compulsive disorder; OCI-R, Obsessive-Compulsive Inventory-Revised; SD, standard deviation; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
†Education was assessed on a scale from 1 to 7.
‡Y-BOCS and age of onset were only applicable in patients.
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a = 0.93 for the OCI-R sum score, a = 0.92 for the
obsessing subscale, and a = 0.89 for the ordering
subscale.
Genotyping
DNA was obtained from blood (n = 458) or saliva
(n = 30) using standard procedures. DNA samples
were genotyped with the Infinium Global Screen-
ing Array (Illumina) according to the manufac-
turer’s instructions. Data were uploaded in the
GenomeStudio 2.0 software and genotypes were
exported in PLINK format. We applied standard
quality control procedures, phasing and imputa-
tion (HRC, Michigan Imputation server), and
adjustments for population structure as described
in the Supplementary Material.
Polygenic risk scores
Summary statistics from the most recent Psychi-
atric Genomics Consortium (PGC) GWAS for
OCD (48), which included 2688 cases and 7037
controls, were used as a discovery sample. Using
PLINK (49), polygenic scores were calculated for
each individual in our target sample from the num-
ber of risk alleles carried for each selected SNP
(imputed dosage, respectively), weighted by the log
(OR) provided by the PGC GWAS, and averaged
across all SNPs. In accordance with practice guide-
lines for PRS analysis (50), SNPs were selected
using different significance thresholds (PT = 0.01,
0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1; see Table S2 for the
number of SNPs included at each threshold). This
resulted in eight continuous PRS that reflect the
genetic risk for OCD at different PT thresholds for
each individual in our target sample based on the
GWAS results of the discovery sample. PRS were
standardized to have a mean of 0 and an SD of 1.
Statistical analyses
To assess group differences in OCD polygenic
scores, ordinal logistic regression models with
group as outcome variable (OCD > rela-
tives > controls) were fitted to the data. Linear
regression analyses were performed to test whether
the OCD polygenic scores predicted levels of harm
avoidance. Normal distribution of residual errors
was verified for all linear regressions. We also
tested whether the association between the PRS
and OCD case/control status was mediated by
harm avoidance using mediation analysis in PRO-
CESS (51). PROCESS is a well-established compu-
tational tool that uses ordinary least squares
regression (and logistic regression for dichotomous
dependent variables, respectively) to estimate the
parameters of each of the equations in a prespeci-
fied model. Here, the PRS was defined as the inde-
pendent variable (X), OCD casesness was the
dependent variable (Y) and harm avoidance was
the mediator (M; model 4 in PROCESS). To assess
mediation, we verified the direct effect of the PRS
on OCD caseness using logistic regression and
employed bootstrapping with 10 000 samples to
compute confidence intervals (CI) and inferential
statistics of the indirect effect of the PRS on OCD
caseness via harm avoidance. In all analyses, the
first two population structure principal compo-
nents were included as covariates to control for
population stratification. The selection of covari-
ates was based on visual inspection of cluster plots
obtained from principal component analysis of the
genetic data. Because the sample included related
individuals, heteroscedasticity-consistent standard
errors were used to account for effects of clustering
within families (HC3; Davidson-MacKinnon) (52).
The models assessing harm avoidance were first
run across all subjects and were then stratified by
group (OCD patient, unaffected relative, healthy
control).
Analogue linear regression analyses were con-
ducted to explore associations between OCD poly-
genic scores, symptom severity (Y-BOCS) and age
of onset. As male gender has repeatedly been
related to an earlier age of onset (53), regression
analyses of OCD onset were stratified by gender.
To account for the observation that OCD symp-
tom dimensions have been differentially linked to
harm avoidance (46, 47), we performed median
splits in OCD patients based on obsessing and
ordering dimensions respectively. Linear regression
analyses as described above were re-run including
OCD patients with obsessing scores ≥ 7 (n = 100)
and ordering scores ≥ 4 (n = 100), respectively, as
assessed by OCI-R. Notably, the resulting subsam-
ples of OCD patients did not exhibit reductions in
mean values or variability of harm avoidance
scores (M = 23.30, SD = 6.58 for patients scoring
high on obsessing, and M = 23.73, SD = 6.87 for
patients scoring high on ordering) as compared to
the full OCD sample (M = 22.18, SD = 6.99).
In the results section, we report the change in R2
between a model only including the covariates and
a model including covariates plus the PRS. Group
differences in harm avoidance were assessed using
analysis of variance (ANOVA) with F-tests and
post hoc Tukey’s tests. Partial eta squared (gp
2)
was used to calculate effect sizes in ANOVA. A P-
value of < 0.05 was considered significant.
Descriptive statistics and distributions of PRS and
harm avoidance scores as well as zero-order
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correlations can be found in the Supplement
(Table S3 and S4; Figures S1–S4).
Results
Harm avoidance significantly differed between
groups (F(2, 485) = 163.34, P < 0.001, gp
2 = 0.40),
with OCD patients showing the highest (P < 0.001
compared to controls) and relatives exhibiting
intermediate scores (P < 0.001 compared to con-
trols).
OCD PRS derived from PGC OCD data were
significantly associated with OCD status (max
DR2 = 0.031, P < 0.001 at PT = 0.3), with patients
having the highest scores and relatives having
intermediate scores (Table 2; Table S5 for more
details; Fig. 1).
OCD PRS were associated with higher levels of
harm avoidance across all subjects (max
DR2 = 0.020, P = 0.0017 at PT = 0.3; Table 3;
Table S6 for more details). This effect was espe-
cially pronounced in OCD patients (max b = 0.15,
P = 0.021 at PT = 0.1; Table S7), while no signifi-
cant associations were observed in unaffected rela-
tives and controls. These results were observed at
multiple PT-value thresholds.
As indicated by mediation analyses, there was a
significant indirect effect of the PRS on OCD case-
ness via harm avoidance at all PT (Table 4). The
association between the PRS and OCD caseness
did not remain significant when harm avoidance
was included in the model (Table 4; Figure S4),
supporting the assumption of a full mediation.
Analyses in OCD patients scoring high on the
obsessing dimension yielded larger effects for the
associations between PRS and harm avoidance
than in the full OCD sample (max b = 0.19,
P = 0.006 at PT = 0.3; Table S8). Analyses in
OCD patients scoring high on the ordering dimen-
sion, on the contrary, yielded less significant results
(max b = 0.17, P = 0.037 at PT = 0.1; Table S9).
Examining relatives and controls who reported a
subclinical obsessing score > 0 (n = 53 and n = 66,
respectively) yielded suggestive associations
between PRS and harm avoidance, as we report in
the Supplement (Table S10). No significant associ-
ations were found in relatives and controls scor-
ing > 0 on the ordering dimension (n = 70 and
n = 107 respectively). Notably, there were no sig-
nificant associations between the OCD PRS and
OCD symptom dimension scores as assessed by
OCI-R subscales among OCD patients
(Table S11).
Since gender differences have been reported for
some aspects of OCD (45), we explored the associ-
ation between OCD PRS and age of onset in gen-
der-stratified samples. OCD PRS at higher PT
thresholds (PT ≥ 0.4) were significantly associated
with an earlier age of OCD onset in male patients
(max b = 0.20, P = 0.036 at PT = 0.5;
Table S12), whereas this comparison was non-sig-
nificant in female patients.
Table 2. Association between OCD polygenic risk scores at different PT thresholds
and group (OCD patients, unaffected first-degree relatives, control subjects). The
change in Nagelkerke pseudo-R2 between a model only including the covariates and
a model including covariates plus the polygenic score is reported, which represents
the additional proportion of variance explained by the polygenic risk score
PT DR
2 Model P OCD polygenic risk score P
0.01 0.011 0.17 0.032
0.05 0.025 0.010 0.001
0.1 0.029 0.004 < 0.001
0.2 0.030 0.004 < 0.001
0.3 0.031 0.003 < 0.001
0.4 0.028 0.005 < 0.001
0.5 0.022 0.017 0.002
1 0.019 0.032 0.003
Fig. 1. Association between OCD polygenic risk scores (z-
scores) and group (OCD patients, unaffected first-degree rela-
tives, control subjects) at PT = 0.3. Error bars indicate stan-
dard errors.
Table 3. Association between OCD polygenic risk scores at different PT thresholds
and harm avoidance across the entire sample. The change in R2 between a model
only including the covariates and a model including covariates plus the polygenic
score is reported
PT DR
2 Model P OCD polygenic risk score P
0.01 0.009 0.15 0.038
0.05 0.014 0.057 0.011
0.1 0.019 0.019 0.0028
0.2 0.018 0.022 0.0032
0.3 0.020 0.013 0.0017
0.4 0.017 0.019 0.0030
0.5 0.013 0.049 0.0093
1 0.010 0.094 0.021
330
Bey et al.
To account for the impact of group differences
in age, all main analyses were re-run with age as a
covariate. Effect sizes remained similar when age
was included in the models. Results also persisted
after the exclusion of patients with a current
comorbid major depressive disorder or any current
comorbid anxiety disorder (see Supplement). We
did not observe any significant associations
between OCD PRS and Y-BOCS severity scores
among OCD patients.
Discussion
The present study investigated whether PRS for
OCD are associated with the personality trait harm
avoidance, which is a promising candidate
endophenotype for OCD, in a sample of OCD
patients, their unaffected first-degree relatives and
healthy controls. Supporting the validity of the
current PGC OCD PRS for out-of-sample predic-
tions, OCD patients had significantly higher scores
than controls, while unaffected relatives showed
intermediate scores. Furthermore, we observed a
significant association between OCD PRS and
harm avoidance throughout the entire sample and
among OCD patients. Mediation analyses indi-
cated that the association between the PRS and
OCD caseness was fully mediated by harm avoid-
ance. These results were observed at multiple P-
value thresholds.
Our findings support the notion that genetic
variants modulating the susceptibility to OCD are
also contributing to harm avoidance, a personality
trait found to be increased in OCD patients. In line
with these results, shared heritability analyses (54)
have revealed a strong and significant genetic cor-
relation between OCD and neuroticism, a con-
struct closely linked to harm avoidance (40, 55).
Importantly, our findings were obtained using
genetic variants which did not reach genome-wide
significance in previous GWAS of OCD, support-
ing the polygenic nature of both OCD and harm
avoidance. Previous GWAS specifically analyzing
harm avoidance did not identify any genome-wide
significant signals (56–58) so that similar to OCD,
a large number of variants appears to contribute to
the genetic component of this trait via small effect
sizes. This notion is further supported by our
observation that effect sizes were largest for the
PRS with a moderate P-value threshold of 0.3,
which appears to achieve a good balance between
capturing a wide range of SNPs with small genetic
contributions and containing noise that inevitably
increases with more liberal P-value thresholds.
Strikingly, the correlation between the OCD
PRS and OCD caseness did not remain significant
when harm avoidance was entered into the model
as a mediator, suggesting that a substantial
amount of the shared variance between the genetic
liability for OCD and the diagnostic phenotype is
accounted for by harm avoidance. We acknowl-
edge that some researchers take the position that
mediation analysis should not be conducted with
cross-sectional data, and we concede that based on
our approach, we cannot infer that associations
were present before manifestation of the disorder.
However, PRS are unchanged from birth through-
out the subjects’ lifetime and can hence be inter-
preted as antecedent predictors of personality
traits and psychopathology. Harm avoidance is
also highly stable across lifetime (21) and even
remains increased in remitted OCD patients com-
pared to healthy controls (59), supporting its trait
nature. The notion that high levels of harm avoid-
ance may be driven by genetic factors is further
supported by findings of increased levels of harm
avoidance in unaffected first-degree relatives of
OCD patients (26–28). In sum, a specific genetic
disposition may result in an increased tendency to
respond intensely to aversive stimuli and in
Table 4. Mediation analysis with OCD polygenic risk score (PRS) as independent variable (X), OCD caseness as dependent variable (Y) and harm avoidance as mediator (M) at
different PT thresholds of the PRS. Effect sizes for caseness prediction are expressed in a log-odds metric. Results for indirect effects are based on 10 000 bootstrapping sam-
ples. Confidence intervals excluding 0 indicate significant effects
Model
Direct effect of X on Y
before mediation
Direct effect of X on Y
after mediation
Direct effect of X on M
before mediation
Indirect effect of X on Y
mediated via M
Direct effect of M on Y
adjusted for X
PT Effect size (SE) P Effect size (SE) P Effect size (SE) P Effect size (SE) 95% CI Effect size (SE) P
0.01 0.24 (0.11) 0.027 0.07 (0.15) 0.62 0.15 (0.05) 0.005 0.33 (0.12) [0.10, 0.59] 2.17 (0.22) <0.001
0.05 0.35 (0.11) 0.001 0.23 (0.15) 0.13 0.17 (0.06) 0.002 0.37 (0.13) [0.14, 0.64] 2.16 (0.21) <0.001
0.1 0.38 (0.11) 0.001 0.20 (0.15) 0.18 0.20 (0.05) <0.001 0.43 (0.13) [0.20, 0.69] 2.15 (0.21) <0.001
0.2 0.37 (0.11) 0.001 0.21 (0.15) 0.16 0.19 (0.05) <0.001 0.40 (0.12) [0.18, 0.66] 2.15 (0.21) <0.001
0.3 0.37 (0.11) 0.001 0.21 (0.15) 0.15 0.19 (0.05) <0.001 0.41 (0.12) [0.18, 0.66] 2.15 (0.21) <0.001
0.4 0.35 (0.11) 0.001 0.19 (0.15) 0.19 0.18 (0.05) <0.001 0.38 (0.12) [0.17, 0.64] 2.15 (0.21) <0.001
0.5 0.31 (0.11) 0.004 0.18 (0.15) 0.21 0.16 (0.05) 0.003 0.34 (0.12) [0.11, 0.58] 2.16 (0.21) <0.001
1 0.29 (0.11) 0.007 0.17 (0.15) 0.24 0.14 (0.05) 0.006 0.31 (0.12) [0.09, 0.56] 2.16 (0.21) <0.001
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interaction with negative life events or early child-
hood trauma, this vulnerability may contribute to
the development of OCD (26).
The observation that harm avoidance mediates
the association between OCD PRS and OCD diag-
nosis highlights the significance of anxiety prone-
ness as a key vulnerability factor for the disease
and supports the traditional classification of OCD
as an anxiety-related disorder. The Research
Domaine Criteria (RDoC) perspective posits that
biologically informed investigations of endopheno-
types will contribute to a more precise classifica-
tion of syndromes, the identification of functional
pathways and improved treatment options (60). In
this regard, our study places harm avoidance on
the functional pathway between genetic liability
and obsessive-compulsive disorder.
Considering potential physiological pathways,
both OCD and harm avoidance are associated
with overlapping aberrations in the functional con-
nectivity of large-scale brain networks (61–64).
Furthermore, patients with OCD robustly exhibit
an increased error-related negativity (ERN), which
is a neural indicator of error monitoring estab-
lished by the anterior cingulate cortex (ACC). An
increased ERN has repeatedly been observed in
unaffected relatives of OCD patients (65) and has
also been found to be linked to harm avoidance in
a subgroup of the present sample (66). Future
investigations should examine whether these over-
lapping brain correlates of harm avoidance and
OCD are driven by the same genetic liability.
We addressed the issue of phenotypic hetero-
geneity in OCD by re-running analyses in OCD
patients that scored high on two specific symptom
dimensions, that is, obsessing and ordering. Con-
sistent with the notion that obsessing is strongly
linked to harm avoidance (46, 47), we found asso-
ciations between OCD PRS and harm avoidance
to be more pronounced in patients with higher
obsessing symptoms than in the full sample. Con-
versely, associations were less pronounced and
only marginally significant in patients with higher
ordering symptoms, which is in line with the obser-
vation that this symptom dimension is less strongly
linked to harm avoidance (46, 47). These findings
suggest that harm avoidance may be a particularly
promising endophenotype for the obsessing sub-
type of OCD. Preliminary evidence from relatives
and controls exhibiting subclinical obsessing symp-
toms also supports this notion. While associations
between PRS and harm avoidance did not reach
significance in the full relatives and controls sam-
ples, explorative analyses in healthy subjects scor-
ing > 0 on the obsessing subscale of the OCI-R
revealed positive correlations between PRS and
harm avoidance. However, these findings should
be interpreted with caution, given the reductions in
sample size.
Despite previous reports of distinct genetic con-
tributions (67, 68), we did not observe any signifi-
cant associations between the OCD PRS and
symptom dimensions as assessed by OCI-R sub-
scales. This suggests that the relationship between
general OCD risk alleles and specific symptom
dimensions is not quantitative but may rather be
characterized by qualitative differences, that is,
specific sets of SNPs or VNTR being linked to
specific symptom dimensions (e.g., 69, 70). A gen-
eral PRS for OCD lumps all of these hypothetical
dimension-specific SNPs together, so that a lack of
an association is not surprising. A recent GWAS
of obsessive-compulsive symptom dimensions also
supports the notion that divergent genes and path-
ways may be involved in the expression of different
symptom dimensions, although no genome-wide
significant SNPs have been found, so far (71).
Further examining the heterogeneity in OCD,
we analyzed associations between OCD PRS and
age of onset. Early age of OCD onset has been
related to male gender, tic disorders, other comor-
bidities and higher familiarity (53, 72), suggesting
distinct etiological pathways. Whereas the odds
ratio of familial recurrence in adult-onset OCD is
approximately 5, it ranges from 12 to 30 for child-
hood-onset OCD (2–4). Here, we observed that in
male patients, a higher OCD PRS was significantly
associated with an earlier age of onset, supporting
the assumption of an increased genetic contribu-
tion in early-onset OCD among male patients.
However, effect sizes were small and given the
reduction of test power in the stratified sample, we
cannot draw definitive conclusion from these
observations.
Notably, OCD symptom severity as assessed by
Y-BOCS was not significantly associated with a
higher genetic risk for OCD. Considering the state
character of symptom severity and the fact that
OCD patients were assessed at different stages of
the disorder and treatment, respectively, this find-
ing appears plausible. Future studies examining
associations between symptom severity and OCD
PRS may record peak symptom severity or con-
duct clinical interviews before or after a standard-
ized treatment. Recently, Alemany-Navarro et al.
found that an OCD PRS was associated with basal
and post-Y-BOCS scores in a sample of 103
patients, but did not predict treatment response to
pharmacotherapy (73). The overall Y-BOCS in our
study was in-between the pre- and post-therapy Y-
BOCS reported by Alemany-Navaro et al. and
showed similar variance. However, Alemany-
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Navaro et al. calculated their PRS using an own
independent sample of 302 cases and 484 controls
rather than using the larger PGC database. Pool-
ing data from well-phenotyped samples and using
ever more precise PRS derived from large GWAS
will reveal whether symptom severity and treat-
ment response are influenced by the same genes
that are related to disease liability.
While several studies have investigated the rela-
tionship between potential endophenotypes and
PRS for schizophrenia, studies on OCD are scarce.
To our knowledge, the present study is the first one
to specifically examine the predictive power of OCD
PRS for a candidate endophenotype. Our findings
show that results from GWAS are valid and trans-
ferable to an independent sample despite the
absence of genome-wide significant hits. A major
strength of the present study is the inclusion of
unaffected first-degree relatives, who have an
increased polygenic risk load but are not afflicted by
the confounds of the disease itself. Another strength
is the homogeneity of methods and endophenotype
assessment. All samples were genotyped at the same
laboratory using the same platform. Processing of
the genetic data, quality control, and imputation
were completed in a uniform way.
The study is not without limitations. First,
although the PGC sample that we used to derive
the PRS is the largest sample currently available, it
is still comparatively small and its power is hence
limited. Notwithstanding, the group differences
observed between OCD patients, unaffected rela-
tives and controls support the validity of the PGC
GWAS and of the PRS based on these data. Sec-
ond, the discovery sample is also relatively small,
which may have contributed to inflations of
explained variance (50). Still, our sample comes
with the advantage of thorough and homogeneous
phenotyping, which becomes more and more diffi-
cult at larger sample sizes. Finding balance
between increasing sample size and maintaining
good phenotype quality is one of the key endeav-
ors for current genetic research. Third, the associa-
tion between OCD PRS and harm avoidance is not
completely independent of covarying group differ-
ences in harm avoidance and polygenic scores. As
these group differences are presumably inherent,
we considered OCD status a moderator rather
than a covariate (74) and ran stratified analyses to
assess effects in each of the three groups. While the
association persisted in the group of OCD patients,
it did not reach significance in relatives and con-
trols, respectively, likely due to reductions in vari-
ance and test power. Notably, OCD patients also
exhibited larger mean values, which may suggest
that the genetic liability has a higher penetrance
for higher levels of harm avoidance. Moreover, we
found evidence that the association between PRS
and harm avoidance was linked to obsessing symp-
toms. This may have also contributed to the lack
of significant effects in relatives and controls, as
these subjects scored comparatively low on the
obsessing dimension in terms of subclinical symp-
toms. Fourth, the association between a genetic
disposition and harm avoidance is likely not speci-
fic to OCD. Since OCD has a large genetic overlap
with other psychiatric disorders (54), and harm
avoidance has also been linked to anxiety and
depression (46, 75), our findings may capture a
transdiagnostic vulnerability for psychiatric disor-
ders. Still, associations between OCD PRS and
harm avoidance remained significant when patients
with comorbid depression or anxiety disorders
were removed, demonstrating that the effect was
not driven by these comorbidities. Future studies
may include clinical comparison groups to further
examine transdiagnostic effects. Fifth, any PRS
only captures additive effects of potential risk alle-
les and does not account for epistasis effects. Fur-
thermore, PRS do not account for the impact of
rare and de novo variants, which have also been
implicated in OCD (8–10). Finally, our cross-sec-
tional study design precludes definite inferences
about causality.
In conclusion, our results support the validity of
harm avoidance as an endophenotype of OCD and
point to common genetic underpinnings. Harm
avoidance appears to mediate the familial risk for
OCD, representing a central vulnerability factor in
the etiology of the disease. Moreover, we found
that in male OCD patients, the OCD PRS was sig-
nificantly associated with an earlier age of onset,
providing further evidence for an increased genetic
contribution in male early-onset OCD.
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